bernhardpucher.com

In a timely manner can be recovered after treatment and rest. Currently, the city has entered the peak flu season in autumn, according to city ILI surveillance results suggest that the number of cases of influenzalike city was no significant difference with previous years. Universities in Shanghai because of the increase in biogenic field, antistress will be a larger flow.

Education, the Municipal Health Bureau issued a "city on the strengthening of institutions at all levels in schools and kindergartens in the fall semester of infectious diseases prevention and control of the circular" the city schools and preschools to seriously implement the control measures, active in the prevention of influenza and influenza A H1N1 influenza health education. Authorities asked students
If flulike symptoms, timely treatment and rest at home until symptoms disappear or return to school after rehabilitation. Recently, the city of Schools, preschools should be combined with school preparation, prevention and control of infectious diseases to further improve the school program and plans to actively organize to prevent influenza, H1N1 knowledge and skills training, to prevent influenza school health
Education as a student’s first lesson, and actively promote healthy living ideas and knowledge of communicable diseases, strengthening health monitoring teachers and students to enhance daily morning health check and sick leave (class) monitoring. Expert, H1N1 highly infectious though, communication is faster, but the present study showed that human infection with influenza A H1N1 influenza virus, the general symptoms are,

Cases, 314 cases of infection for the territory. So far, the Mainland of China had reported 3,757 cases of swine influenza H1N1 confirmed cases, 3,249 cases have been cured, not because of influenza caused by H1N1 influenza deaths. Deputy Health Minister Yin Li pointed out yesterday, H1N1 is a new fat people are generally susceptible diseases affecting human health has
Become a global public health events. Recently, in some countries and regions of the severe and deaths on the rise. China is seeing a spread of the epidemic and the possibility of severe cases even death still exists. Recently, the World Health Organization warned: the spread of influenza A H1N1 influenza virus, the speed is incredible, and in the proportion
Of deaths in young adults is relatively high. With the advent of autumn and winter, increasing the risk of spread of the epidemic. At the same time, the possibility of the virus have mutated. The number of influenzalike illness in Shanghai was no significant difference in previous years, the new semester just around the corner, according to City Board of

The product more than 90. By the end of the year, the institute plans to produce 80000001000 million doses of vaccine supply market, production capacity and supply capacity of the largest. This reporter has learned, Shanghai Institute of Biological Products in June 18 was the World Health Organization’s influenza A H1N1 influenza virus seed. In the speedy completion of a
Series of standardized procedures, July 25 and entered the doubleblind, randomized human clinical trial to test as many as 1980 people. August 26, Chinese Centre for Disease Control and Prevention clinical trials, "Exposing blind": Domestic swine H1N1 influenza virus vaccine in cracking over 90, to reach and exceed the provisions of the State Food and Drug Administration assessment of the
Immunogenicity of standard . More than 3700 cases diagnosed Mainland spread of the epidemic is still possible to inform the Ministry of Health on August 31, at 15 o’clock on the August 28 to at 15 o’clock on the August 31, China’s mainland New Influenza H1N1 confirmed cases of 359 cases of influenza, of which 45 cases were outside imported

Conditions what kind of order of vaccination." Chinese Health Minister Chen Zhu also attended the World Health Ministers in July during the period that China has 1.3 billion people, it is difficult in the short term while providing vaccine to everyone. Therefore, once the vaccine into the immunization phase, the first step will be vaccinated susceptible population, such as pregnant
Women, people with basic diseases, and workers in special fields. Ministry of Health Committee of Experts will also be produced according to the development of the state of domestic and international characteristics of the epidemic, and continuously dynamic adjustment strategy. Morning Post yesterday learned from relevant departments of the city, first produced in Shanghai about a flu vaccine available. It
Is reported that the first batch of Shanghai Biological Products Research Institute of Influenza A H1N1 influenza vaccine production has been finished samples sent to the Pharmaceutical and Biological Products, completed the final test, the first batch of more than 40,000 bottles of a flu vaccine can be available. The rigorous doubleblind clinical trial revealed that the immune effect of

"Once students have influenza symptoms, timely treatment and rest at home until the symptoms disappear or rehabilitation and then return to school." Critical time, domestic vaccine successful review yesterday, this week is expected to get the production batch number. 360 yearolds only 1 inoculation needle, I believe you can stay away from the virus. Review is examining the success of
Domestic vaccine immunization strategy According to Xinhua, the State Food and Drug Administration yesterday organized a vaccination expert review meeting will be, after deliberations by the Beijing Sinovac Biotech Co., Ltd. Production of influenza A H1N1 influenza vaccine has been reviewed by expert groups, and allowed to full production are used in human immunization. Reportedly, the vaccine market will be
Under the unified arrangement of the prevention and control will not be panic buying. Ministry of Health, Office of the Deputy Director of Health Emergency, said Liang years earlier, the use of vaccine immunization strategy to emphasize, not everyone is vaccinated. Experts are studying the final vaccine vaccination strategies, "may be listed in focus groups, high risk, and under what

Influenza vaccine clinical trial. Preliminary results show the vaccine is safe and effective on the human body. The results showed that clinical trials of vaccination with one dose of vaccine can produce a good immune response, indicating that vaccination can protect the human body. The subjects after vaccination no serious adverse reactions, adverse reactions with mild, transient the reactions, the
Main symptom is pain at the injection site, indicating that the vaccine has a good safety. Has to monitor a normal flow before a sudden escalation in the primary and secondary school trend. The Ministry of Health yesterday issued the whole of society Influenza H1N1 influenza prevention and control initiative to require schools and kindergartens to strengthen prevention and control
To guard against a stream after the fall semester in a school outbreak of epidemic. Health education to Students, adhere to a daily morning check and a "zero report" system. In hardhit areas, authorities enterprises to reduce crossborder interprovincial nonessential travel, to avoid meeting. Shanghai Municipal Education Commission, the Municipal Bureau of Health jointly issued an emergency notice also asked,

Of age or older group (101 patients) ,1860yearold adult group (706 cases) ,1217yearold group (404 cases), 311yearolds group (403 cases) 4 group were inoculated, of which the old age group inoculated a needle; adult groups, youth groups and children in group 2 needle inoculation. July 28, Beijing Sinovac Biotech Co., Ltd., said, H1N1 vaccine clinical trials progressing well, all subjects
Completed the first needle inoculation and observation of safety for 3 days, no serious adverse reaction reports, preliminary results Show vaccine safety. August 12, H1N1 vaccine clinical trials, subjects began the second needle inoculation, Health Minister Chen Zhu as the first subjects on the afternoon of 11 completed the second needle inoculation. In the first observation of needle vaccination, no
Serious adverse reactions or events, preliminary analysis shows that the production of influenza A H1N1 influenza in China with the vaccine safe and reliable test. August 18, Beijing Branch Star Biological Products Co., Ltd. announced that its production of influenza A H1N1 influenza vaccine clinical trials completed, and this is the world’s first preliminary evaluation of the influenza A H1N1

Responsible for mandays revealed that at present, exfactory price of ordinary flu vaccine is about 30 yuan. Since A is the independent research and development of influenza vaccines, so prices should not be higher than the price of ordinary flu vaccine. Events domestic vaccine production June 8, H1N1 Vaccine Virus Strains NYMCX179A arrived in Beijing Sinovac Biotech Co., Ltd., research
Strains of seed lots quickly start preparation work, marking the mass production of influenza H1N1 vaccine was officially launched. June 13, Beijing Sinovac Biotech Company Limited said, H1N1 vaccine is still in the preparation of "seed" virus of the training phase, the first week after the vaccine will be officially put into operation in Beijing. June 15, Beijing Sinovac Biotech
Co., Ltd. completed the strains of influenza A H1N1 influenza vaccine seed grant preparation work and put into production on the same day the first batch of vaccine. July 22, Beijing Sinovac Biotech Co., Ltd. Production of influenza A H1N1 influenza vaccine, the completion of biological, chemical and biological experiments, started clinical trials. 1614 volunteers were divided into 60 years

Laboratory to get the vaccine production strains, and vaccine development work began. The State Food and Drug Administration spokeswoman Yan Jiangying, said, H1N1 is a new virus, not only eager to influenza H1N1 influenza vaccine is the most important is to ensure safe and effective vaccines and quality control. Vaccine produced will be conducted after rigorous clinical tests, the SFDA
Will organize and coordinate the relevant departments, and vaccine development, production, testing, distribution, use of links to full control. (Xinhua Ye Chau) Yangtze Evening News reported on September 1 at the State Food and Drug Administration Center for Drug Evaluation, held on August 31 the first time, a flu vaccine expert review meeting, Beijing Sinovac Biotech Co., Ltd. produced by
Influenza A H1N1 influenza split vaccine expert technical review, expected within this week, a drug approval number, which means domestic swine influenza H1N1 vaccine will be formally put into use. Beijing vaccine development company, said the responsible person, a flu vaccine to be inoculated before and after the two needles. According to the national pandemic influenza vaccine production company is